Kenneth J Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1479744/publications.pdf

Version: 2024-02-01

126907 206112 3,807 191 33 48 citations h-index g-index papers 192 192 192 5042 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cost Impact of Molecular Testing for Indeterminate Thyroid Nodule Fine-Needle Aspiration Biopsies. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1905-1912.	3.6	131
2	Cost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Clinical Infectious Diseases, 2007, 44, 1280-1288.	5.8	125
3	Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine. JAMA - Journal of the American Medical Association, 2012, 307, 804-12.	7.4	115
4	Use of personal protective equipment among health care personnel: Results of clinical observations and simulations. American Journal of Infection Control, 2017, 45, 17-23.	2.3	97
5	Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism. Chest, 2005, 128, 1601-1610.	0.8	87
6	Cost-effectiveness of newer treatment strategies for influenza. American Journal of Medicine, 2002, 113, 300-307.	1.5	84
7	Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer, 2015, 15, 62.	2.6	69
8	Universal Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Surveillance for Adults at Hospital Admission: An Economic Model and Analysis. Infection Control and Hospital Epidemiology, 2010, 31, 598-606.	1.8	63
9	Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. Infection Control and Hospital Epidemiology, 2015, 36, 438-444.	1.8	63
10	The Cost-Effectiveness of Sildenafil. Annals of Internal Medicine, 2000, 132, 933.	3.9	62
11	Alternative strategies for adult pneumococcal polysaccharide vaccination: A cost-effectiveness analysis. Vaccine, 2008, 26, 1420-1431.	3.8	59
12	Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Advances, 2018, 2, 1792-1798.	5.2	56
13	Prediction of Pelvic Inflammatory Disease Among Young, Single, Sexually Active Women. Sexually Transmitted Diseases, 2006, 33, 137-142.	1.7	51
14	Transoral Robotic Surgery and the Unknown Primary: A Costâ€Effectiveness Analysis. Otolaryngology - Head and Neck Surgery, 2014, 150, 976-982.	1.9	47
15	Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine, 2010, 28, 7731-7736.	3.8	46
16	Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage. Anesthesiology, 2018, 128, 328-337.	2.5	45
17	Cost-Effectiveness Analysis of Single Fraction ofÂStereotactic Body Radiation Therapy Compared With Single Fraction of External Beam Radiation Therapy for Palliation of Vertebral Bone Metastases. International Journal of Radiation Oncology Biology Physics, 2015, 91, 556-563.	0.8	44
18	To Test or to Treat? An Analysis of Influenza Testing and Antiviral Treatment Strategies Using Economic Computer Modeling. PLoS ONE, 2010, 5, e11284.	2.5	42

#	Article	IF	Citations
19	The Cost-Effectiveness of Immediate Treatment, Percutaneous Biopsy and Active Surveillance for the Diagnosis of the Small Solid Renal Mass: Evidence From a Markov Model. Journal of Urology, 2012, 187, 39-43.	0.4	42
20	Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer. Brachytherapy, 2015, 14, 29-36.	0.5	40
21	Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Older Adults. American Journal of Preventive Medicine, 2013, 44, 373-381.	3.0	39
22	Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecologic Oncology, 2011, 122, 473-478.	1.4	37
23	The costâ€effectiveness of communityâ€based screening for oral cancer in highâ€risk males in the United States: A Markov decision analysis approach. Laryngoscope, 2011, 121, 952-960.	2.0	36
24	Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A U.S. perspective. Thrombosis Research, 2013, 132, 647-651.	1.7	35
25	Cost-Effectiveness of Procalcitonin-Guided Antibiotic Therapy for Outpatient Management of Acute Respiratory Tract Infections in Adults. Journal of General Internal Medicine, 2014, 29, 579-586.	2.6	35
26	A cost-effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children. Pediatric Blood and Cancer, 2010, 55, 1153-1159.	1.5	34
27	Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine, 2010, 28, 5952-5959.	3.8	34
28	Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement. Pharmacoeconomics, 2010, 28, 521-538.	3.3	34
29	Costâ€effectiveness of endoscopic sphenopalatine artery ligation versus nasal packing as firstâ€line treatment for posterior epistaxis. International Forum of Allergy and Rhinology, 2013, 3, 563-566.	2.8	34
30	Probability of pregnancy after sterilization: a comparison of hysteroscopic versus laparoscopic sterilization. Contraception, 2014, 90, 174-181.	1.5	34
31	Costâ€Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. Journal of the American Geriatrics Society, 2016, 64, 2126-2131.	2.6	34
32	Economic Evaluation of Standing Order Programs for Pneumococcal Vaccination of Hospitalized Elderly Patients. Infection Control and Hospital Epidemiology, 2008, 29, 385-394.	1.8	33
33	Quality of Life Utilities for Pelvic Inflammatory Disease Health States. Sexually Transmitted Diseases, 2008, 35, 307-311.	1.7	33
34	Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine, 2013, 31, 3950-3956.	3.8	33
35	Costâ€effectiveness of new antiviral regimens for treatmentâ€naÃ⁻ve U.S. veterans with hepatitis C. Hepatology, 2016, 63, 428-436.	7.3	33
36	The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis. BMC Infectious Diseases, 2016, 16, 655.	2.9	33

#	Article	IF	Citations
37	A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatric Blood and Cancer, 2007, 48, 173-180.	1.5	32
38	Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. American Journal of Medicine, 2005, 118 , $625-635$.	1.5	31
39	Sequential Medication Strategies for Postherpetic Neuralgia: A Cost-Effectiveness Analysis. Journal of Pain, 2007, 8, 396-404.	1.4	31
40	Potential unintended pregnancies averted and cost savings associated with a revised Medicaid sterilization policy. Contraception, 2013, 88, 691-696.	1.5	31
41	A cluster randomized trial of a primary palliative care intervention (CONNECT) for patients with advanced cancer: Protocol and key design considerations. Contemporary Clinical Trials, 2017, 54, 98-104.	1.8	31
42	Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007. Preventing Chronic Disease, 2010, 7, A109.	3.4	31
43	Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients. Journal of Vascular Surgery, 2010, 52, 1537-1545.e2.	1.1	30
44	Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine, 2010, 28, 7620-7625.	3.8	30
45	The potential economic value of a hookworm vaccine. Vaccine, 2011, 29, 1201-1210.	3.8	30
46	Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value in Health, 2016, 19, 326-334.	0.3	30
47	Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. Journal of Vascular Surgery, 2018, 67, 343-352.	1.1	30
48	Antiviral Therapies for Herpes Zoster Infections. Pharmacoeconomics, 2000, 18, 95-104.	3.3	29
49	Economic value of norovirus outbreak control measures in healthcare settings. Clinical Microbiology and Infection, 2011, 17, 640-646.	6.0	29
50	Effect of an Oncology Nurse–Led Primary Palliative Care Intervention on Patients With Advanced Cancer. JAMA Internal Medicine, 2021, 181, 1451.	5.1	29
51	Should Vascular Surgery Patients Be Screened Preoperatively for Methicillin-Resistant <i>Staphylococcus aureus</i> !> Infection Control and Hospital Epidemiology, 2009, 30, 1158-1165.	1.8	28
52	The timing of influenza vaccination for older adults (65 years and older). Vaccine, 2009, 27, 7110-7115.	3.8	27
53	Reliability of Laparoscopic Compared With Hysteroscopic Sterilization at 1 Year. Obstetrics and Gynecology, 2011, 118, 273-279.	2.4	27
54	A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children. Journal of Pediatrics, 2017, 189, 54-60.e3.	1.8	27

#	Article	IF	CITATIONS
55	Cost Comparisons between Home- and Clinic-Based Testing for Sexually Transmitted Diseases in High-Risk Young Women. Infectious Diseases in Obstetrics and Gynecology, 2007, 2007, 1-5.	1.5	26
56	Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers. Clinical Microbiology and Infection, 2010, 16, 1740-1746.	6.0	26
57	Impact of Pharmacist-Managed Erythropoiesis-Stimulating Agents Clinics for Patients With Non–Dialysis-Dependent CKD. American Journal of Kidney Diseases, 2012, 60, 371-379.	1.9	26
58	Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thrombosis and Haemostasis, 2005, 93, 592-599.	3.4	25
59	Cost-Effectiveness of Procalcitonin-Guided Antibiotic Use in Community Acquired Pneumonia. Journal of General Internal Medicine, 2013, 28, 1157-1164.	2.6	25
60	Cost-Effectiveness of Routine Surveillance Endomyocardial Biopsy After 12 Months Post–Heart Transplantation. Circulation: Heart Failure, 2014, 7, 807-813.	3.9	24
61	Comparison of Listing Strategies for Allosensitized Heart Transplant Candidates Requiring Transplant at High Urgency: A Decision Model Analysis. American Journal of Transplantation, 2015, 15, 427-435.	4.7	24
62	Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1175-1183.	0.8	24
63	Economic analysis of screening for subclinical rejection in kidney transplantation using protocol biopsies and noninvasive biomarkers. American Journal of Transplantation, 2021, 21, 186-197.	4.7	24
64	Using Thrombophilia Testing to Determine Anticoagulation Duration in Pediatric Thrombosis is not Cost-Effective. Journal of Pediatrics, 2009, 155, 100-104.	1.8	23
65	Exercise, Manual Therapy, and Booster Sessions in Knee Osteoarthritis: Cost-Effectiveness Analysis From a Multicenter Randomized Controlled Trial. Physical Therapy, 2018, 98, 16-27.	2.4	23
66	Quality-of-Life Utility Values for???Erectile Function and Sildenafil Treatment. Clinical Drug Investigation, 2005, 25, 99-105.	2.2	22
67	Hospitalization for Pelvic Inflammatory Disease: A Cost-Effectiveness Analysis. Sexually Transmitted Diseases, 2007, 34, 108-112.	1.7	22
68	Retropubic and transobturator midurethral slings: a decision analysis to compare outcomes including efficacy and complications. International Urogynecology Journal, 2010, 21, 787-793.	1.4	22
69	Cost-Effectiveness of Implantable Cardioverter-Defibrillators inÂChildren With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2010, 16, 734-741.	1.7	22
70	A costâ€effectiveness analysis of positron emission tomographyâ€computed tomography surveillance versus upâ€front neck dissection for management of the neck for N2 disease after chemoradiotherapy. Laryngoscope, 2012, 122, 311-314.	2.0	22
71	Cost effectiveness of an internet-delivered lifestyle intervention in primary care patients with high cardiovascular risk. Preventive Medicine, 2016, 87, 103-109.	3.4	22
72	Supraorbital Versus Endoscopic Endonasal Approaches for Olfactory Groove Meningiomas: A Cost-Minimization Study. World Neurosurgery, 2017, 105, 126-136.	1.3	22

#	Article	IF	CITATIONS
73	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thrombosis Research, 2017, 150, 123-130.	1.7	22
74	Time from Sexually Transmitted Infection Acquisition to Pelvic Inflammatory Disease Development: Influence on the Cost-Effectiveness of Different Screening Intervals. Value in Health, 2007, 10, 358-366.	0.3	21
7 5	Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use?. Thrombosis and Haemostasis, 2008, 100, 447-452.	3.4	21
76	The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA. Clinical Microbiology and Infection, 2011, 17, 1717-1726.	6.0	21
77	Cost-Utility Analysis of von Willebrand Disease Screening in Adolescents with Menorrhagia. Journal of Pediatrics, 2010, 157, 456-460.e1.	1.8	19
78	Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine. CNS Drugs, 2010, 24, 695-712.	5.9	19
79	A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age) Tj ETQq1	1 0.784314 3.8	rgBT /Overlo
80	Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine, 2011, 29, 3525-3530.	3.8	18
81	Comparing the Air Medical Prehospital Triage Score With Current Practice for Triage of Injured Patients to Helicopter Emergency Medical Services. JAMA Surgery, 2018, 153, 261.	4.3	18
82	Economics of influenza vaccine administration timing for children. American Journal of Managed Care, 2010, 16, e75-e85.	1.1	18
83	Cost-Effectiveness of Implementing the Chronic Care Model for Diabetes Care in a Military Population. Journal of Diabetes Science and Technology, 2011, 5, 501-513.	2.2	17
84	Interventionist training and intervention fidelity monitoring and maintenance for CONNECT, a nurse-led primary palliative care in oncology trial. Contemporary Clinical Trials Communications, 2018, 10, 57-61.	1.1	17
85	Hope and advance care planning in advanced cancer: Is there a relationship?. Cancer, 2022, 128, 1339-1345.	4.1	17
86	Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis. International Urogynecology Journal, 2009, 20, 933-938.	1.4	16
87	Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria. American Journal of Clinical Nutrition, 2020, 111, 141-148.	4.7	16
88	InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence. Female Pelvic Medicine and Reconstructive Surgery, 2011, 17, 199-203.	1.1	16
89	Costâ€Effectiveness of Screening for Unhealthy Alcohol Use with %Carbohydrate Deficient Transferrin: Results From a Literatureâ€Based Decision Analytic Computer Model. Alcoholism: Clinical and Experimental Research, 2009, 33, 1440-1449.	2.4	15
90	Financial Implications of 12-Month Dispensing of Oral Contraceptive Pills in the Veterans Affairs Health Care System. JAMA Internal Medicine, 2019, 179, 1201.	5.1	15

#	Article	IF	Citations
91	Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study. Vaccine, 2017, 35, 3974-3981.	3.8	14
92	Cost-effectiveness of increasing vaccination in high-risk adults aged 18–64ÂYears: a model-based decision analysis. BMC Infectious Diseases, 2018, 18, 52.	2.9	14
93	Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study. American Journal of Epidemiology, 2017, 185, 822-831.	3.4	13
94	Hypertension with unsatisfactory sleep health (HUSH): study protocol for a randomized controlled trial. Trials, 2017, 18, 256.	1.6	13
95	Mobility and Vitality Lifestyle Program (MOVE UP): A Community Health Worker Intervention for Older Adults With Obesity to Improve Weight, Health, and Physical Function. Innovation in Aging, 2018, 2, igy012.	0.1	13
96	Cost-Effectiveness of Alternative Outpatient Pelvic Inflammatory Disease Treatment Strategies. Sexually Transmitted Diseases, 2007, 34, 960-966.	1.7	12
97	Costâ€ldentification Analysis of Total Laryngectomy. Otolaryngology - Head and Neck Surgery, 2011, 144, 220-224.	1.9	12
98	Incremental Cost Effectiveness of Pharmacist-Managed Erythropoiesis-Stimulating Agent Clinics for Non-Dialysis-Dependent Chronic Kidney Disease Patients. Applied Health Economics and Health Policy, 2013, 11, 653-660.	2.1	12
99	Costâ€effectiveness analysis of two caries prevention methods in the first permanent molar in children. Journal of Public Health Dentistry, 2018, 78, 118-126.	1.2	12
100	Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50–64†years compared to the US general population. Vaccine, 2019, 37, 2026-2033.	3.8	12
101	Oneâ€year costâ€effectiveness of callosotomy vs vagus nerve stimulation for drugâ€resistant seizures in Lennoxâ€Gastaut Syndrome: A decision analytic model. Epilepsia Open, 2022, 7, 124-130.	2.4	12
102	Cost Effectiveness of Newer Antiviral Agents for Herpes Zoster: Is the Evidence Spotty?. Journal of Infectious Diseases, 1998, 178, S85-S90.	4.0	11
103	Direct Paramedic Transport of Acute Myocardial Infarction Patients to Percutaneous Coronary Intervention Centers: A Decision Analysis. Annals of Emergency Medicine, 2009, 53, 233-240.e5.	0.6	11
104	Cost Effectiveness of Influenza Vaccine for U.S. Children. American Journal of Preventive Medicine, 2016, 51, 309-317.	3.0	11
105	Automated Communication Tools and Computer-Based Medication Reconciliation to Decrease Hospital Discharge Medication Errors. American Journal of Medical Quality, 2016, 31, 315-322.	0.5	11
106	Costâ€Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. Journal of the American Geriatrics Society, 2017, 65, 763-768.	2.6	11
107	Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults. Vaccine, 2017, 35, 5708-5713.	3.8	11
108	Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S Journal of the National Medical Association, 2019, 111, 540-545.	0.8	11

#	Article	IF	Citations
109	Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thrombosis and Haemostasis, 2008, 100, 447-52.	3.4	11
110	Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis. Vaccine, 2009, 27, 3159-3164.	3.8	10
111	Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation. Thrombosis and Haemostasis, 2012, 108, 303-310.	3.4	10
112	Managing mesh exposure following vaginal prolapse repair: a decision analysis comparing conservative versus surgical treatment. International Urogynecology Journal, 2013, 24, 119-125.	1.4	10
113	Promoting Organ Donor Registries Through Public Education. Transplantation, 2016, 100, 1332-1338.	1.0	10
114	Cost-Effectiveness Analysis of a Military Hearing Conservation Program. Military Medicine, 2018, 183, e547-e553.	0.8	10
115	Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. American Journal of Cardiovascular Drugs, 2018, 18, 317-325.	2.2	10
116	Cost-Utility of Antimicrobial Prophylaxis for Treatment of Children With Vesicoureteral Reflux. Frontiers in Pediatrics, 2019, 7, 530.	1.9	10
117	Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors. American Journal of Preventive Medicine, 2021, 61, 28-36.	3.0	10
118	Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sexually Transmitted Diseases, 2007, 34, 960-6.	1.7	10
119	Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States. BMC Public Health, 2014, 14, 718.	2.9	9
120	Cost-Effectiveness of Decision Support Strategies in Acute Bronchitis. Journal of General Internal Medicine, 2015, 30, 1505-1510.	2.6	9
121	An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis. Human Vaccines and Immunotherapeutics, 2019, 15, 863-872.	3.3	9
122	Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations. American Journal of Preventive Medicine, 2020, 58, 487-495.	3.0	9
123	Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria. American Journal of Clinical Nutrition, 2021, 113, 172-178.	4.7	9
124	Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic. American Journal of Managed Care, 2010, 16, 200-6.	1.1	9
125	The potential economic value of a Staphylococcus aureus vaccine for neonates. Vaccine, 2010, 28, 4653-4660.	3.8	8
126	Cost-effectiveness of workplace wellness to prevent cardiovascular events among U.S. firefighters. BMC Cardiovascular Disorders, 2016, 16, 229.	1.7	8

#	Article	IF	Citations
127	Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2–8 Years in the U.S American Journal of Preventive Medicine, 2016, 50, 600-608.	3.0	8
128	Cost-Effectiveness of Ventricular Assist Device Destination Therapy for Advanced Heart Failure in Duchenne Muscular Dystrophy. Pediatric Cardiology, 2018, 39, 1242-1248.	1.3	8
129	Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease. Value in Health, 2018, 21, 1365-1372.	0.3	8
130	Characterization of a factor IX variant with a glycine 207 to glutamic acid mutation. Blood, 1994, 84, 1866-1873.	1.4	7
131	Cost-Effectiveness of a Program to Eliminate Disparities in Pneumococcal Vaccination Rates in Elderly Minority Populations: An Exploratory Analysis. Value in Health, 2013, 16, 311-317.	0.3	7
132	Impact of seasonal influenza vaccination in the presence of vaccine interference. Vaccine, 2018, 36, 853-858.	3.8	7
133	Costâ€effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. Head and Neck, 2018, 40, 1743-1751.	2.0	7
134	Cost-Effectiveness of Pneumococcal VaccinationÂand Uptake ImprovementÂPrograms in Underserved and General Population Adults Aged < 65ÂYears. Journal of Community Health, 2020, 45, 111-120.	3.8	7
135	Costâ€Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations. Journal of the American Geriatrics Society, 2020, 68, 1271-1278.	2.6	7
136	Costâ€Effectiveness of Primary Liver Transplantation Versus Hepatoportoenterostomy in the Management of Biliary Atresia in the United States. Liver Transplantation, 2021, 27, 711-718.	2.4	7
137	Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 2564-2572.	2.3	6
138	Comparing Microvascular Decompression with Gamma Knife Radiosurgery for Trigeminal Neuralgia. A Cost-Effectiveness Analysis. World Neurosurgery, 2019, 125, 207-216.	1.3	6
139	A comparative cost-utility analysis of postoperative calcium supplementation strategies used in the current management of hypocalcemia. Surgery, 2020, 167, 137-143.	1.9	6
140	Lungâ€Specific Risk Factors Associated With Incident Hip Fracture in Current and Former Smokers. Journal of Bone and Mineral Research, 2020, 35, 1952-1961.	2.8	6
141	Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. American Journal of Managed Care, 2013, 19, e30-7.	1.1	6
142	Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox*. Pharmacoeconomics, 1998, 13, 645-651.	3.3	5
143	Incremental cost-effectiveness of various monthly doses of vardenafil. Value in Health, 2011, 14, 97-101.	0.3	5
144	Cost-Effectiveness of Pediatric Heart Transplantation Across a Positive Crossmatch for High Waitlist Urgency Candidates. American Journal of Transplantation, 2015, 15, 2978-2985.	4.7	5

#	Article	IF	CITATIONS
145	Cost-Effectiveness Analysis of Biological Signature DCISionRT Use for DCIS Treatment. Clinical Breast Cancer, 2021, 21, e271-e278.	2.4	5
146	Weight Loss through Lifestyle Intervention Improves Mobility in Older Adults. Gerontologist, The, 2022, 62, 931-941.	3.9	5
147	Costâ€effectiveness of ethanol lock prophylaxis to prevent central line–associated bloodstream infections in children with intestinal failure in the United States. Journal of Parenteral and Enteral Nutrition, 2022, 46, 324-329.	2.6	5
148	Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder. American Journal of Managed Care, 2013, 19, e55-63.	1.1	5
149	Information primary care physicians want to receive about their hospitalized patients. Family Medicine, 2012, 44, 425-30.	0.5	5
150	Determining the cost–effectiveness of adult pneumococcal vaccination strategies. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 1-4.	1.4	4
151	Three Cost-utility Analyses of Screening for Intracranial Hemorrhage in Neonates With Hemophilia. Journal of Pediatric Hematology/Oncology, 2014, 36, 474-479.	0.6	4
152	Economic Analysis of Universal Active Surveillance Screening for Methicillin-Resistant <i>Staphylococcus aureus</i> : Perspective Matters. Infection Control and Hospital Epidemiology, 2015, 36, 14-16.	1.8	4
153	Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy. Value in Health, 2016, 19, 537-543.	0.3	4
154	Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old. Human Vaccines and Immunotherapeutics, 2017, 13, 2207-2212.	3.3	4
155	Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis. American Journal of Preventive Medicine, 2019, 56, e135-e141.	3.0	4
156	Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non–Small Cell Lung Cancer Based on Mutational Status. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 837-844.	1.3	4
157	Identification of Abusive Head Trauma in High-Risk Infants: AÂCost-Effectiveness Analysis. Journal of Pediatrics, 2020, 227, 176-183.e3.	1.8	4
158	Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults. Innovation in Aging, 2018, 2, igy035.	0.1	3
159	Exploring the potential public health benefits of universal influenza vaccine. Human Vaccines and Immunotherapeutics, 2019, 15, 2919-2926.	3.3	3
160	Cost-Effectiveness of a Radio Frequency Hemostatic Sealer (RFHS) in Adult Spinal Deformity Surgery. World Neurosurgery, 2019, 122, 171-175.	1.3	3
161	Exploratory Cost-Effectiveness Analysis for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: Is Linezolid or Daptomycin Favored Over Vancomycin?. Clinical Drug Investigation, 2021, 41, 885-894.	2.2	3
162	AIDS-Associated Non-Hodgkin's Lymphomas as Primary and Secondary AIDS Diagnoses in Hemophiliacs. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 78-86.	0.3	3

#	Article	IF	CITATIONS
163	Anticoagulation duration in heterozygous factor V Leiden: A decision analysis. Thrombosis Research, 2013, 132, 724-728.	1.7	2
164	Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers. Oncology Research, 2015, 22, 311-319.	1.5	2
165	Microsimulation Model to Compare Enteral and Parenteral Iron Supplementation in Children With Intestinal Failure. Journal of Parenteral and Enteral Nutrition, 2021, 45, 810-817.	2.6	2
166	Cost-Effectiveness of Prophylactic Cranial Irradiation Versus MRI Surveillance for Extensive-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1186-1194.	0.8	2
167	Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes. Journal of Comparative Effectiveness Research, 2021, 10, 1133-1141.	1.4	2
168	Effects of an Oncology Nurse-Led, Primary Palliative Care Intervention (CONNECT) on Illness Expectations Among Patients With Advanced Cancer. JCO Oncology Practice, 2022, 18, e504-e515.	2.9	2
169	Imaging versus Intervention in Managing Small Unruptured Intracranial Aneurysms: A Cost-Effectiveness Analysis. Cerebrovascular Diseases, 2021, , 1-11.	1.7	2
170	Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA. Infectious Diseases and Therapy, 0, , .	4.0	2
171	Teaching Medical Decision Modeling: A Qualitative Description of Student Errors and Curriculum Responses. Medical Decision Making, 2006, 26, 583-588.	2.4	1
172	The Authors' Reply. Pharmacoeconomics, 2010, 28, 782-784.	3.3	1
173	Herpes Zoster Vaccine and Older Adults. JAMA - Journal of the American Medical Association, 2011, 305, 1410.	7.4	1
174	Potential Consequences of Not Using Live Attenuated Influenza Vaccine. American Journal of Preventive Medicine, 2017, 53, 500-503.	3.0	1
175	Reply to: Estimating the Full Value of Highâ€Dose Influenza Vaccine. Journal of the American Geriatrics Society, 2017, 65, 2111-2112.	2.6	1
176	A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 290-298.	4.5	1
177	Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis. Vaccine, 2021, 39, 4278-4282.	3.8	1
178	Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Î' value of information analysis. Vaccine, 2021, 39, 3608-3613.	3.8	1
179	Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism Blood, 2012, 120, 3177-3177.	1.4	1
180	Are Current Recommendations for Antiviral Therapy of Herpes Zoster Cost-Effective?. Journal of General Internal Medicine, 2000, 15, 4-4.	2.6	1

#	Article	IF	CITATIONS
181	Treatment of Acute Childhood Idiopathic Thrombocytopenic Purpura (ITP): A Cost-Utility Analysis Blood, 2005, 106, 1337-1337.	1.4	1
182	Risk-stratification in febrile infants 29 to 60 days old: a cost-effectiveness analysis. BMC Pediatrics, 2022, 22, 79.	1.7	1
183	Is Radiation Therapy Cost-Effective in the Positron Emission Tomography/Computed Tomography Era for Early-Stage Favorable Hodgkin Lymphoma With Alternative Payment Models?. Practical Radiation Oncology, 2022, 12, e135-e143.	2.1	1
184	Current practices in lipid emulsion utilization in the prevention and treatment of intestinal failure–associated liver disease: A survey of pediatric intestinal rehabilitation and transplant centers. Journal of Parenteral and Enteral Nutrition, 2022, 46, 1585-1592.	2.6	1
185	Pharmacoeconomics of antiviral therapies for Herpes zoster infections. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 527-534.	1.4	O
186	Decreasing Trends of Healthcare-Associated Infections: Multifactorial Synergy. Infection Control and Hospital Epidemiology, 2015, 36, 656-657.	1.8	0
187	Cost-Effectiveness of Single Versus Confirmatory Urinalysis in the Evaluation of Asymptomatic Microhematuria. Urology Practice, 2018, 5, 427-432.	0.5	O
188	Cost Effectiveness Strategy to Predict Postoperative Bleeding in Von Willebrand Disease Blood, 2008, 112, 1295-1295.	1.4	0
189	A Cost-Effectiveness Analysis of Coagulation Testing Prior to Tonsillectomy and Adenoidectomy in Children Blood, 2008, 112, 1294-1294.	1.4	0
190	Anticoagulation in Ambulatory Cancer Patients. Blood, 2011, 118, 2071-2071.	1.4	0
191	Investigation into the Cost-Effectiveness of Extended Posttraumatic Thromboprophylaxis. Journal of the American College of Surgeons, 2022, 234, 86-94.	0.5	O